Inhalable Therapies
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
32
NCT06896890
Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer
Phase: Phase 1/2
Role: Lead Sponsor
Start: Jun 23, 2023
Completion: Oct 1, 2026
Loading map...